Drug intelligence / Profile preview

NOVS-100

Development stage: Preclinical
Lead developer: Celloram
Modality: Small Molecules

Overview

NOVS-100 is a drug candidate initially developed by Celloram, Inc. It functions as an inhibitor of Fatty Acid Binding Protein 4 (FABP4) and Fatty Acid Binding Protein 5 (FABP5). By targeting these proteins, NOVS-100 aims to modulate lipid metabolism and inflammatory pathways. The drug is currently in preclinical development and is being investigated for its potential therapeutic applications in various conditions, including neoplasms, skin and musculoskeletal diseases, and inflammation, with a specific focus on Triple Negative Breast Cancer.

Targets

FABP5 (Fatty acid-binding protein 5)FABP4 (Fatty acid-binding protein 4)

Beyond the preview

Go deeper on NOVS-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NOVS-100.

Explore the full profile